Myfortic (Mycophenolic Acid)

Mycophenolic Acid, the active ingredient in Myfortic, is an immunosuppressant presented as a tablet for oral use. It helps prevent organ rejection in renal and other solid organ transplant recipients by inhibiting lymphocyte proliferation. The product is authorized in the European Union and is prescribed by transplant specialists to maintain graft function.

GNH USA supplies Myfortic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, and pharmacies worldwide, ensuring quality and regulatory compliance through reliable distribution networks.

Myfortic is an immunosuppressant used in transplant medicine to reduce the risk of organ rejection.

Renal transplant: prevents rejection of kidney grafts. Other solid organ transplant: prevents rejection of liver, heart, lung, and other grafts. Maintenance therapy: maintains graft function after the initial post‑transplant period.

Myfortic may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Vomiting - Headache - Upper respiratory tract infection - Abdominal pain

Serious or Rare Side Effects: - Leukopenia or neutropenia - Anemia - Severe infections (e.g., opportunistic infections) - Hepatic dysfunction - Progressive multifocal leukoencephalopathy (PML) - Malignancies

When prescribing Myfortic, clinicians should consider several safety measures.

Monitor blood counts: perform regular complete blood count assessments. Assess renal function: check serum creatinine and glomerular filtration rate periodically. Evaluate for infections: watch for signs of opportunistic or severe infections. Avoid use in pregnancy: contraindicated unless benefits outweigh risks (Category D). Store at ambient temperature: keep tablets below 25 °C in the original pack, protected from moisture.

Myfortic can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Live vaccines: increased risk of infection. - Azathioprine: additive myelosuppression. - Cholestyramine or other bile‑acid sequestrants: reduced absorption. - Antacids containing aluminum or magnesium: may affect bioavailability. - Strong CYP3A4 inducers (e.g., rifampin): lower drug levels.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for bleeding risk. - ACE inhibitors or ARBs: watch renal function. - NSAIDs: increased risk of renal toxicity. - Antiviral agents (e.g., acyclovir): potential dose adjustment. - Diuretics: monitor electrolyte balance.